|Velox CD Vascular Closure Device--Courtesy of Transluminal|
Transluminal Technologies last week announced that it has received a CE mark for the bioresorbable Velox CD Vascular Closure Device for hemostasis, or stopping bleeding, in the thigh's femoral artery following percutaneous procedures, or those involving needle puncture.
The device delivers an implant made of a magnesium alloy that plugs the cut in the artery wall and is then absorbed by the body within two weeks. Syracuse, NY-based Transluminal claims that the product is the world's first metal-based bioresorbable closure device for hemostasis in surgeries using a femoral access point.
"Velox CD is a true next generation vascular closure device that addresses the shortcomings of extant products with vastly improved implant delivery and bioabsorption technologies," said company president Stephen Green in a statement. Transluminal says the product reduces the need for manual compression and enables faster patient recovery post surgery.
This marks another development for bioresorbable devices, which eliminate complications associated with permanent implants. Meanwhile, the race is on to sell the first FDA-approved bioresorbable stent for the coronary artery, a more difficult task than plugging a wound following surgery. Two devices for the coronary artery have CE marks. Of the market's contenders, only Biotronik's clinical-stage stent is using a metal-based material, similar to that employed by the Velox CD.
- read the release
Special Report: Leaders emerge in the race for the first U.S. bioresorbable stent